icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020
Back grey_arrow_rt.gif
 
 
 
Modeling-Supported Islatravir Dose Selection for Phase 3
 
 
  Reported by Jules Levin
 
Deanne Jackson Rudd; Youfang Cao; Pavan Vaddady; Jay A. Grobler; Ernest Asante-Appiah; Tracy Diamond; Stephanie Klopfer; Anjana Grandhi; Peter Sklar; Carey Hwang; Ryan Vargo Merck & Co., Inc., Kenilworth, NJ, USA
 
CROI: Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
 
CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
 
CROI: Weekly Islatravir Protects Monkeys Against IV Challenge With SIV - Mark Mascolini (03/11/20)

0312201

0312202

0312203

0312204

0312205

0312206

0312207

0312208